Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: Double-blind randomised controlled trial

Lancet

Volumn 363, Issue 9424, 2004, Pages 1843-1848

  Alloueche, A ⁱ   Bailey, W ^m   Barton, S ^k   Bwika, J ^a   Chimpeni, P ^b   Falade, C O ^c   Fehintola, F A ^c   Horton, J ^d   Jaffar, S ⁱ   Kanyok, T ^j   Kremsner, P G ^e,f   Kublin, J G ^b,h   Lang, T ^k   Missinou, M A ^e,f   Mkandala, C ^b   Oduola, A M J ^c   Premji, Z ^g   Robertson, L ^l   Sowunmi, A ^c   Ward, S A ^m   Winstanley, P A ^d   more..

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^c UNIVERSITY OF IBADAN   (Nigeria)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ALBERT SCHWEITZER HOSPITAL   (Gabon)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g MUHIMBILI MEDICAL CENTRE   (Tanzania)

^h University of Maryland School of Medicine Center for Vaccine Development   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k GLAXOSMITHKLINE   (United Kingdom)

^l Statwood Partnership   (United Kingdom)

^m LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL PLUS DAPSONE; FANSIDAR;

ABDOMINAL PAIN; AFRICA; ANEMIA; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GAMETOCYTEMIA; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBIN DETERMINATION; HEMOGLOBINOPATHY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; METHEMOGLOBINEMIA; MULTICENTER STUDY; NEUTROPHILIA; PARASITOSIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 2942623924     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16350-2     Document Type: Article

References (30)

1. World Health Organization.The use of antimalarial drugs: report of a WHO informal consultation, Nov 13-17, 2000 - WHO/CDS/RBM/2001.33. Geneva: WHO, 2000.
2. Watkins WM, Mosobo M. Treatment of plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 87:1993;75-78
3. Watkins WM, Mberu EK, Winstanley PA, Plowe C. The efficacy of antifolate combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 13:1997;459-464
4. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci. 357:2002;505-519
5. Snow RW, Eckert E, Teklehaimanot A. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol. 19:2003;363-369
6. Nzila A, Nduati E, Mberu E, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long acting antifolate pyrimethamine/sulfadoxine compared with the shorter acting chlorproguanil- dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 181:2000;2023-2028
7. Mutabingwa T, Nzila A, Mberu E, et al. Drug resistant falciparum malaria in Tanzania: chlorproguanil-dapsone is effective treatment for infections resistant to pyrimethamine-sulfadoxine. Lancet. 358:2001;1218-1223
8. Kublin JG, Dzinjalamala F, Kamwendo D, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 185:2001;380-388
9. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanil-dapsone: an effective treatment for uncomplicated falciparum malaria. Anti Microb Ag Chemother. 41:1997;2261-2264
10. Sulo J, Chimpeni P, Hatcher J, et al. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet. 360:2002;1136-1143
11. Winstanley PA, Watkins WM, Muhia D, Szwandt S, Amukoye E, Marsh K. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg. 91:1997;322-327
12. Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. 91:1997;719-724
13. World Health Organization Division of Control of Tropical Diseases. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission - WHO/MAL/96.1077. 1996;WHO, Geneva
14. World Health Organization Department of Communicable Diseases, Surveillance and Response and WHO Roll Back Malaria. Monitoring antimalarial drug resistance: report of a WHO consultation, Dec 3 - 5, 2001 - WHO/CDS/CSR/EPH/2002.17MAL/96.1077. @ Geneva: WHO, 2002.
15. Von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, Targett G. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health. 6:2001;92-98
16. Dollery C, ed. Dapsone. Therapeutic drugs (second edn). London: Churchill Livingstone, 1999: 13-18.
17. Alloueche A, Silveira H, Conway D, et al. High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Mol Biochem Parasitol. 106:2000;273-282
18. Bradley D, Newbold C.I, Warrell DA. Malaria. In: The Oxford textbook of medicine (third edn). Oxford: Oxford University Press, 1996: 835-63.
19. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, Alloueche A, Warhurst DC. Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. J Infect Dis. 186:2002;1861-1864
20. Ansah EK, Gyapong JO, Agyepong IA, Evans DB. Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup. Trop Med Int Health. 6:2001;496-504
21. Smith RP. Toxic responses of the blood. Klaasen DC, Amdur OM, Doull J. Cassaret and Doull's Toxicologythe basic science of poisons. 1996;335-350 McGraw Hill, New York
22. Jollow DJ, McMillan DC. Oxidative stress, glucose-6-phosphate dehydrogenase and the red cell. Adv Exp Med Biol. 500:2001;595-605
23. Carrazza M, Carrazz F, Oga S. Clinical and laboratory parameters in dapsone acute intoxication. Rev Saude Publica. 34:2000;396-401
24. Luzatto L. Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Weatherall DJ, Ledingham JGG, Warrell DA. The Oxford textbook of medicine. third edn:1996;Oxford University Press, Oxford
25. Hirono A, Beutler E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc Nat Acad Sci USA. 85:1988;3951-3954
26. Vulliamy TJ, Othman A, Town M. Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. Proc Natl Acad Sci USA. 88:1991;8568-8571
27. Beutler E, Kuhl W. Vives-Corrons J, Prchal J. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood. 74:1989;2550-2555
28. Ruwende C, Khoo S, Snow R, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 376:1995;246-249
29. International artemisinin study group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 363:2004;9-17
30. MMV Annual report 2002, page 17. Available at http://www.mmv.org/ FilesUpld/53.pdf (accessed December, 2003).